Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 07 March 2012 | By Alexander Gaffney, RAC
Senator Chuck Grassley (R-IA) and
Representative Darrell Issa (R-CA) sent a letter to the US Food and Drug
Administration (FDA) about their monitoring of nine employees who worked for
the agency. The letter demands a comprehensive explanation of all FDA
monitoring policies after the agency kept tabs on emails sent by the nine
workers to federal watchdog agencies.
In the letter, sent to Office of Management and Budget (OMB) Acting Budget Director Jeffery Zients, Grassley and Issa state that FDA's monitoring of the actions of its employees "was not lawful."
"To the extent that it monitored communications with the Congress and the Office of Special Counsel (OSC), the FDA was not legitimately investigating wrongdoing or tracing a security breach. Disclosures to OSC and Congress are authorized and protected by law," continued Grassley and Issa.
Their letter goes on to request that OMB collect information on whether or not FDA employees-and those of other agencies-are permitted minimal use of personal email at work, whether FDA has an official policy for monitoring employee email, what communications are legally protected, the extent of monitoring activities, the titles of FDA officials authorized to order or conduct surveillance and statistics on monitoring activities.
Letter - To The Honorable Jeffery D. Zients
Regulatory Focus - Whistleblowers Accuse FDA of Monitoring Correspondence to Congress About Medical Device Concerns
Regulatory Focus - Senator Grassley Expresses 'Concern' About FDA Treatment of Whistleblowers, Opens Investigation
Regulatory Focus - Investigation into FDA Handling of Whistleblowers Widens
The Hill - Republicans question extent of agencies' spying on federal employees
Tags: Surveillance, Zients, FDA Nine, OSC, Issa, Monitoring, OMB, Investigation, Letter, Latest News, Grassley
Regulatory Focus newsletters
All the biggest regulatory news and happenings.
This article provides a variety of websites with important information on recent changes to FDA guidances and tables ...